Polynovo is a medical devices business based in Australia. Polynovo shares (PNV) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Polynovo has a trailing 12-month revenue of around $103.2 million. If you're looking to buy shares, check out the steps below.
To buy shares listed in Australia such as Polynovo, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose or you can see our list of the best share trading platforms in Australia. Then follow these steps.
Our top pick for
Best for day trading
Our top pick for
Education & learning
Our top pick for
Low commission
| 52-week range | $1.095 - $2.78 |
|---|---|
| 50-day moving average | $2.4548 |
| 200-day moving average | $2.1169 |
| Target price | $2.4 |
| PE ratio | 233 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.01 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$2.58
| 1 week (2024-09-06) | 10.73% |
|---|---|
| 1 month (2024-08-14) | 0.39% |
| 3 months (2024-06-14) | 10.26% |
| 6 months (2024-03-14) | 11.21% |
| 1 year (2023-09-14) | 96.20% |
|---|---|
| 2 years (2022-09-14) | 82.33% |
| 3 years (2021-09-14) | 29.97% |
| 5 years (2019-09-13) | 22.86% |
Valuing Polynovo stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Polynovo's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Polynovo's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 233x. In other words, Polynovo shares trade at around 233x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Polynovo's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.6 million (£0.0 million).
The EBITDA is a measure of a Polynovo's overall financial performance and is widely used to measure stock profitability.
| Revenue TTM | $103.2 million |
|---|---|
| Operating margin TTM | 1.83% |
| Gross profit TTM | $53.8 million |
| Return on assets TTM | 0.56% |
| Return on equity TTM | 7.65% |
| Profit margin | 5.1% |
| Book value | 0.104 |
| Market capitalisation | $1.6 billion |
TTM: trailing 12 months
We're not expecting Polynovo to pay a dividend over the next 12 months.
Polynovo's shares were split on a 0.1429:1 basis on 2 May 2004. So if you had owned 1 share the day before the split, the next day you would own 0.1429 shares. This wouldn't directly have changed the overall worth of your Polynovo shares – just the quantity. However, indirectly, the new 599.8% higher share price could have impacted the market appetite for Polynovo shares which in turn could have impacted Polynovo's share price.
Over the last 12 months, Polynovo's shares have ranged in value from as little as $1.095 up to $2.78. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Polynovo's is 1.669. This would suggest that Polynovo's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
We put Australia's top funds to the test against ChatGPT and Google's Bard to see which stock portfolio's were the best performing.
CHESS sponsorship allows you to directly own ASX listed shares in your own name, but it comes with some drawbacks. Find out if it's right for you.
Looking for the best performing stocks in Australia? We update this list weekly.
If you're thinking of trading stocks with Tiger Brokers, check out our review of this online broker's fees, safety and pros and cons first.
Here's what investors should know before adding AI stocks to their portfolios.
Find out the different ways you can invest in the S&P 500 index from Australia.
Saxo Invested allows you to trade over 60,000 instruments on 50 global stock exchanges and provides lower commissions for active traders.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
A dividend is the distribution of some of a company's profits that are paid regularly to its shareholders.
Follow these tips to find the best share trading platform for you.